The use of captopril in 19 patients with renal parenchymal disease and refractory hypertension was studied for a mean period of 12 months. There was a significant reduction in the systolic and diastolic blood pressures, with a reduction in the mean arterial pressure of 29 mmHg. The mean maintenance dose of captopril was 142 mg daily in three divided doses. All but one of the patients required a diuretic for satisfactory blood pressure control and 3 patients were also given a beta-blocker. In all patients a simplification of the previous therapeutic regimen was achieved. A significant rise in serum creatinine was noted in 2 patients, one of whom had to be withdrawn from the study. Despite the presence of renal functional impairment, proteinuria did not occur de novo nor did established proteinuria increase. Leukopenia was not noted in any of the patients in this group.
Introduction
The orally active angiotensin-converting enzyme inhibitor, captopril, is now accepted as a useful drug in the treatment of essential and non-essential hypertension irrespective of causes (Case et al. 1978 , Brunner et al. 1979 , Ferguson et al. 1980 , Gavras et al. 1978 . Its efficacy in renovascular hypertension (Case et al. 1982 , Atkinson et al. 1979 , where the reninangiotensin-aldosterone system is of pathogenic importance, is predictable but its success in the other types of hypertension is more difficult to explain. Changes in sodium balance and reduction in extracellular fluid, or the accumulation of endogenous vasodilating substances such as kinins and prostaglandins, have been postulated (Case et al. 1977 , Crantz et al. 1979 , McGiff& Quilley 1980 , Moore et al. 1981 , Murthy et al. 1978 , Marks et al. 1980 . The use of captopril in patients with renal impairment is not yet established. We have studied the use of captopril in patients with renal parenchymal disease, 3 of whom had renovascular hypertension. The results, toxic effects and reasons for withdrawal of the drug in this group of patients are detailed and the current criteria for the use of captopril in patients with impaired renal function are reviewed.
Patients and methods
Nineteen patients (8 males, 11 females, mean age + s.e. (mean) 51.2 + 3.9 years), all with impaired renal function as evidenced by a reduction in endogenous creatinine clearance, were treated with captopril. When this study was initiated, captopril was restricted by special licence to individual patients with severe hypertension refractory to combination triple therapy. Eighteen of the patients were selected because of poor blood pressure control on adequate conventional combination therapy of beta-blockers, diuretics and vasodilators. In the remaining patient who had scleroderma, captopril was substituted as the drug of choice because of the reported improvement in peripheral perfusion in addition to control of blood pressure (D'Angelo et al. 1980) . The titration phase of therapy was undertaken in hospital and patients were discharged when adequate blood pressure control was achieved. They were subsequently seen monthly to assess blood pressure control and to observe the appearance of side effects. In the later stages of the study, some of the patients with good blood pressure control were reviewed at 3-monthly intervals. Blood pressures were measured in the supine position with a standard mercury sphygmomanometer, and the disappearance of the Korotkoff sounds (phase 5) was taken as the diastolic pressure. Serum electrolytes, creatinine, urea, blood counts and endogenous creatinine clearance were monitored in all patients on therapy. All results in this study are expressed as the mean ± s.e. (mean). Student's t test was used for statistical comparison of paired data before and after captopril therapy.
Results
Blood pressure: A significant and sustained reduction of systolic and diastolic blood pressure was achieved in all patients throughout the period of observation after initial stabilization. The mean arterial pressure on combination therapy prior to the introduction of captopril was 134.5 +2.5 mmHg and was reduced to 105.3 +2.3 mmHg (P<0.005) after a mean duration of 12 months' therapy ( Figure 1 ). This reduction was achieved with the concomitant use of diuretics in 18 patients and the addition of beta-blockers in 3 patients. The use of nifedipine in one patient for the treatment of severe angina prior to commencement of captopril was continued subsequently. Six patients developed symptomatic hypotension (systolic <90 mmHg) after the initial test dose of captopril; all of these patients had been on diuretics prior to commencement of the drug. There were no subsequent episodes of symptomatic hypotension in any of the patients. The heart rate did not change significantly in any of the patients after the introduction of captopril therapy.
Dosage regimen: All patients were treated initially with captopril 25 mg three times daily, after an initial 12.5 mg test dose. The mean maintenance dose was 142 mg daily (range 75-300 mg daily) administered in 3 divided doses. Only one of the 19 patients achieved satisfactory control on captopril alone; all the other patients required a diuretic and in addition 3 patients were given beta-blockers. Potassium supplements were necessary in one patient, and in another given the potassium sparing amiloride, hyperkalemia developed. In all patients a-marked <0.001 simplification of the therapeutic regimen was possible with consequent improved compliance (Table 1) .
Laboratory tests: There was a significant rise in the mean serum creatinine (P < 0.05) and urea (P<0.001), but no significant change in creatinine clearance (Table 2) . There was no significant alteration in serum potassium following captopril therapy. Four patients had a substantial rise in serum creatinine and urea following captopril therapy. The drug was discontinued in one of these patients because his serum creatinine rose from 480 jimol/l to 850 jmol/l and because he developed uraemic symptoms. The serum creatinine reverted towards baseline (520 j.mol/l) two months later. The rise in creatinine in two patients was probably not significant in view of their already marked renal functional impairment. The improvement in serum creatinine in one patient was attributed to bilateral percutaneous transluminal angioplasty soon after the introduction of captopril.
Side effects and reasons for withdrawal: During the period of observation no evidence of leukopenia or other blood dyscrasia was noted. One patient discontinued therapy after 13 months' satisfactory blood pressure control due to the cost of the drug, after supplies for the trial were exhausted. The drug was withdrawn in one patient because captopril was not licenced for use in pregnancy. Another patient in end-stage renal failure became normotensive after initiation of chronic haemodialysis. The patient with deteriorating renal function referred to already is improving after withdrawal of the drug. One patient died froroncardiac failure following a myocardial infarction and in one patient the drug was withdrawn because of anorexia, loss of taste and mouth ulceration. Diminished taste sensation in one patient and increase in appetite in another were not sufficiently severe to warrant withdrawal of captopril. Proteinuria did not occur de novo nor did established proteinuria increase in any of the patients.
Discussion
The present study confirms others (Gavras et al. 1978 , Raine & Ledingham 1982 , Havelka et al. 1982a , Hamilton et al. 1981 ) that captopril is an effective antihypertensive agent for the treatment of resistant hypertension in patients with renal functional impairment. The absence of reflex tachycardia in association with antihypertensive efficacy is probably related to alteration in autonomic function in hypertensive subjects (Mancia et al. 1982 ) and to combined arteriolar and venous dilatation (Tarazi 1978 , Tarazi et al. 1980 . The mean dose of captopril required to achieve satisfactory control of blood pressure in the present series was similar to that reported by other investigators (Case et al. 1982 , Havelka et al. 1982a with comparable patient groups. The dose was much higher than that used by others (McGregor et al. 1979 , Veterans Administration Co-operative Study Group 1982 ) whose patient groups were dissimilar in one, or more respects: notably, pathogenesis of hypertension, absence of renal functional impairment, or lack of adequate prior combination antihypertensive therapy. Many recent studies suggest that a diuretic is a valuable adjunct during captopril therapy. Some studies suggest that once a basic treatment level of 25 mg (three times daily) of the drug has been attained, blood pressure control can be improved by either adding-in or increasing the dose of diuretic rather than augmenting captopril dosage (Brunner et al. 1979 , Ferguson et al. 1980 , Case et al. 1982 , McGregor et al. 1979 , Veterans Administration Co-operative Study Group 1982 , Atkinson et al. 1980a , Andren et al. 1982 , Santucci et al. 1982 . This manoeuvre was not attempted in our series but may have allowed a reduction in our higher mean daily dose. We found both loop and thiazide-type diuretics equally effective as adjunctive agents. The addition of beta-blockers to a diuretic-captopril regimen has also been advocated for adequate control of blood pressure in a proportion of patients (Ferguson et al. 1980 , Case et al. 1982 , Havelka et al. 1982a . Only 3 patients in this series required the addition of beta-blockers, a lesser incidence than reported by others.
Very little information is available on the long-term use of captopril in patients with renal impairment (Raine & Ledingham 1982 , Havelka et al. 1982a ,b, Hamilton et al. 1981 ) though there have been case reports of reversible renal failure associated with captopril (Havelka et al. 1982a , Collste et al. 1979 , Prins et al. 1979 , Seedat 1980 , Grossman et al. 1980 , Woodhouse et at. 1979 , Farrow & Wilkinson 1979 , Hricik et al. 1983 , Curtis et al. 1983 . Captopril has been shown to increase renal blood flow in patients with essential hypertension and under some circumstances to increase the glomerular filtration rate . A disturbance in the autoregulation of glomerular filtration consequent to blockade of the renin-angiotensin system in the presence of reduced renal artery perfusion pressure has been proposed as a likely cause of captopril-induced renal insufficiency (Hricik et al. 1983 , Curtis et al. 1983 . The possibility that this drug may be nephrotoxic (Case et al. 1980 , Kincaid-Smith et al. 1980 , Hoorntje et al. 1980 or that it may impair renal function must be considered when assessing the benefits of captopril therapy against side effects. Four of the 19 patients studied developed an increase in serum creatinine and in one a probable relationship with therapy was established by the improvement after withdrawal of the drug. Similar findings have been reported by others (Grossman et al. 1980 , Woodhouse et al. 1979 , Farrow & Wilkinson 1979 , Hricik et al. 1983 ). If captopril is to be used in renal failure, close monitoring of renal function is essential and early withdrawal of the drug in those with accelerated deterioration in renal function is mandatory. The side effects of captopril, in particular leukopenia and proteinuria, are reported to be more marked in patients with pre-existing impairment of renal function (Havelka et al. 1982a , Forslund et al. 1981 , Heel et al. 1980 , Staessen et al. 1980 , Case et al. 1980 , Gavras et al. 1981 . Despite significant renal functional impairment in our patients, proteinuria did not occur de novo, nor did established proteinuria increase. Leukopenia was not noted in any patient. Loss of taste and mouth ulceration are uncomfortable but not life-threatening for the patient and usually respond to reduction in captopril dosage (Havelka et al. 1982a) .
A precipitous reduction in blood pressure with the first dose was noted in 6 of our patients and has been reported by others (Case et al. 1978 , Havelka et al. 1982b , Atkinson et al. 1980a . It therefore seems advisable that in treatment-resistant hypertensives the change to captopril therapy should be carried out in the hospital setting. This precaution should be particularly observed in patients previously on diuretics whose potential sodium depletion may render them more sensitive to captopril. Although the role of capropril is now generally established in the treatment of hypertension, its safety is not yet as clear cut. We found it safe and effective in a group of patients with renal parenchymal disease and impaired renal function with a tolerable level of side effects, but caution is advised and close monitoring of renal function is essential.
